Standard BioTools Inc. (LAB) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 6 Buy, 4 Hold.
The consensus price target is $3.25, representing an upside of 232.5% from the current price $0.98.
Analysts estimate Earnings Per Share (EPS) of $-0.36 and revenue of $0.17B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.52 vs est $-0.36 (missed -45.8%). 2025: actual $-0.20 vs est $-0.21 (beat +3.5%). Analyst accuracy: 83%.
LAB Stock — 12-Month Price Forecast
$3.25
▲ +232.48% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Standard BioTools Inc., the price target is $3.25.
The average price target represents a +232.48% change from the last price of $0.98.
LAB Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Standard BioTools Inc. in the past 3 months
EPS Estimates — LAB
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.52
vs Est –$0.36
▼ 31.4% off
2025
Actual –$0.20
vs Est –$0.21
▲ 3.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — LAB
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.174B
vs Est $0.171B
▲ 1.9% off
2025
Actual $0.085B
vs Est $0.080B
▲ 5.9% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
